Assessment of temporal association of relapse of canine multicentric lymphoma with components of the CHOP protocol: Is cyclophosphamide the weakest link?
•Dogs with lymphoma relapsed significantly more frequently when cyclophosphamide was used as an induction agent.•New chemotherapy protocols which replace cyclophosphamide with other agent/s might improve outcomes.•The cumulative or synergistic effects of previously used drugs did not affect treatmen...
Gespeichert in:
| Veröffentlicht in: | The veterinary journal (1997) 2016-07, Vol.213, p.87-89 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 89 |
|---|---|
| container_issue | |
| container_start_page | 87 |
| container_title | The veterinary journal (1997) |
| container_volume | 213 |
| creator | Wang, Shang-Lin Lee, Jih-Jong Liao, Albert Taiching |
| description | •Dogs with lymphoma relapsed significantly more frequently when cyclophosphamide was used as an induction agent.•New chemotherapy protocols which replace cyclophosphamide with other agent/s might improve outcomes.•The cumulative or synergistic effects of previously used drugs did not affect treatment.•Relatively higher dose rates in small dogs may produce better responses and longer remission times.
Combination chemotherapy, using cyclophosphamide, hydroxydaunorubicin, vincristine and prednisolone (CHOP), is the most commonly used treatment for canine lymphoma. Most affected dogs respond during the initial stages of chemotherapy, but many relapse. The aim of this study was to evaluate the relationship between the use of specific chemotherapy drugs and clinical relapse, using the modified Madison-Wisconsin, 25 week chemotherapy protocol. Forty-one of 68 dogs affected with multicentric lymphoma relapsed during the treatment period. Relapse occurred more frequently after the administration of cyclophosphamide (n = 24; P |
| doi_str_mv | 10.1016/j.tvjl.2016.04.013 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1793216165</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1090023316300351</els_id><sourcerecordid>1793216165</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-adfa27a0a35828b1289d6d9025e3b7445f5671bb0f0d143095987b7375765a5c3</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhSMEoqXwAiyQl2wS_BPHE4SEqhHQSpXKAtaW49xoPLXj4OtpNY_C2-J0CktWPvL9zrGvTlW9ZbRhlHUf9k2-3_uGF93QtqFMPKvOmRS85r1iz4umPa0pF-KseoW4p5T2bctfVmdc8Zb2nJ9Xvy8RATHAnEmcSIawxGQ8MYjROpNdnNf7BN4sCKu0ZnYzkHDw2dliS84SfwzLLgZDHlzeERtLyFxG-Bi5A7K9uv1OlhRztNF_JNdI7NH6WDy47ExwIzxiD2DuADPxbr77_Lp6MRmP8ObpvKh-fv3yY3tV39x-u95e3tRWyC7XZpwMV4YaITd8MzC-6cdu7CmXIAbVtnKSnWLDQCc6slbQXvYbNSihpOqkkVZcVO9PueV_vw7leR0cWvDezBAPqJnqBWcd62RB-Qm1KSImmPSSXDDpqBnVayV6r9dK9FqJpq0ulRTTu6f8wxBg_Gf520EBPp0AKFveO0garYPZwugS2KzH6P6X_wf6A5-l</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1793216165</pqid></control><display><type>article</type><title>Assessment of temporal association of relapse of canine multicentric lymphoma with components of the CHOP protocol: Is cyclophosphamide the weakest link?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Wang, Shang-Lin ; Lee, Jih-Jong ; Liao, Albert Taiching</creator><creatorcontrib>Wang, Shang-Lin ; Lee, Jih-Jong ; Liao, Albert Taiching</creatorcontrib><description>•Dogs with lymphoma relapsed significantly more frequently when cyclophosphamide was used as an induction agent.•New chemotherapy protocols which replace cyclophosphamide with other agent/s might improve outcomes.•The cumulative or synergistic effects of previously used drugs did not affect treatment.•Relatively higher dose rates in small dogs may produce better responses and longer remission times.
Combination chemotherapy, using cyclophosphamide, hydroxydaunorubicin, vincristine and prednisolone (CHOP), is the most commonly used treatment for canine lymphoma. Most affected dogs respond during the initial stages of chemotherapy, but many relapse. The aim of this study was to evaluate the relationship between the use of specific chemotherapy drugs and clinical relapse, using the modified Madison-Wisconsin, 25 week chemotherapy protocol. Forty-one of 68 dogs affected with multicentric lymphoma relapsed during the treatment period. Relapse occurred more frequently after the administration of cyclophosphamide (n = 24; P < 0.01), compared with vincristine (n = 9) or doxorubicin (n = 5). Therefore, the therapeutic outcome of traditional CHOP-based chemotherapy might be improved by replacing cyclophosphamide with other cytotoxic drugs.</description><identifier>ISSN: 1090-0233</identifier><identifier>EISSN: 1532-2971</identifier><identifier>DOI: 10.1016/j.tvjl.2016.04.013</identifier><identifier>PMID: 27240922</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Animals ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Canine ; Chemotherapy ; Cyclophosphamide ; Cyclophosphamide - therapeutic use ; Dog Diseases - drug therapy ; Dogs ; Doxorubicin - therapeutic use ; Female ; Lymphoma ; Lymphoma - drug therapy ; Lymphoma - veterinary ; Male ; Prednisone - therapeutic use ; Recurrence ; Relapse ; Vincristine - therapeutic use</subject><ispartof>The veterinary journal (1997), 2016-07, Vol.213, p.87-89</ispartof><rights>2016 Elsevier Ltd</rights><rights>Copyright © 2016 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-adfa27a0a35828b1289d6d9025e3b7445f5671bb0f0d143095987b7375765a5c3</citedby><cites>FETCH-LOGICAL-c356t-adfa27a0a35828b1289d6d9025e3b7445f5671bb0f0d143095987b7375765a5c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.tvjl.2016.04.013$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27240922$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Shang-Lin</creatorcontrib><creatorcontrib>Lee, Jih-Jong</creatorcontrib><creatorcontrib>Liao, Albert Taiching</creatorcontrib><title>Assessment of temporal association of relapse of canine multicentric lymphoma with components of the CHOP protocol: Is cyclophosphamide the weakest link?</title><title>The veterinary journal (1997)</title><addtitle>Vet J</addtitle><description>•Dogs with lymphoma relapsed significantly more frequently when cyclophosphamide was used as an induction agent.•New chemotherapy protocols which replace cyclophosphamide with other agent/s might improve outcomes.•The cumulative or synergistic effects of previously used drugs did not affect treatment.•Relatively higher dose rates in small dogs may produce better responses and longer remission times.
Combination chemotherapy, using cyclophosphamide, hydroxydaunorubicin, vincristine and prednisolone (CHOP), is the most commonly used treatment for canine lymphoma. Most affected dogs respond during the initial stages of chemotherapy, but many relapse. The aim of this study was to evaluate the relationship between the use of specific chemotherapy drugs and clinical relapse, using the modified Madison-Wisconsin, 25 week chemotherapy protocol. Forty-one of 68 dogs affected with multicentric lymphoma relapsed during the treatment period. Relapse occurred more frequently after the administration of cyclophosphamide (n = 24; P < 0.01), compared with vincristine (n = 9) or doxorubicin (n = 5). Therefore, the therapeutic outcome of traditional CHOP-based chemotherapy might be improved by replacing cyclophosphamide with other cytotoxic drugs.</description><subject>Animals</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Canine</subject><subject>Chemotherapy</subject><subject>Cyclophosphamide</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Dog Diseases - drug therapy</subject><subject>Dogs</subject><subject>Doxorubicin - therapeutic use</subject><subject>Female</subject><subject>Lymphoma</subject><subject>Lymphoma - drug therapy</subject><subject>Lymphoma - veterinary</subject><subject>Male</subject><subject>Prednisone - therapeutic use</subject><subject>Recurrence</subject><subject>Relapse</subject><subject>Vincristine - therapeutic use</subject><issn>1090-0233</issn><issn>1532-2971</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1DAUhSMEoqXwAiyQl2wS_BPHE4SEqhHQSpXKAtaW49xoPLXj4OtpNY_C2-J0CktWPvL9zrGvTlW9ZbRhlHUf9k2-3_uGF93QtqFMPKvOmRS85r1iz4umPa0pF-KseoW4p5T2bctfVmdc8Zb2nJ9Xvy8RATHAnEmcSIawxGQ8MYjROpNdnNf7BN4sCKu0ZnYzkHDw2dliS84SfwzLLgZDHlzeERtLyFxG-Bi5A7K9uv1OlhRztNF_JNdI7NH6WDy47ExwIzxiD2DuADPxbr77_Lp6MRmP8ObpvKh-fv3yY3tV39x-u95e3tRWyC7XZpwMV4YaITd8MzC-6cdu7CmXIAbVtnKSnWLDQCc6slbQXvYbNSihpOqkkVZcVO9PueV_vw7leR0cWvDezBAPqJnqBWcd62RB-Qm1KSImmPSSXDDpqBnVayV6r9dK9FqJpq0ulRTTu6f8wxBg_Gf520EBPp0AKFveO0garYPZwugS2KzH6P6X_wf6A5-l</recordid><startdate>201607</startdate><enddate>201607</enddate><creator>Wang, Shang-Lin</creator><creator>Lee, Jih-Jong</creator><creator>Liao, Albert Taiching</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201607</creationdate><title>Assessment of temporal association of relapse of canine multicentric lymphoma with components of the CHOP protocol: Is cyclophosphamide the weakest link?</title><author>Wang, Shang-Lin ; Lee, Jih-Jong ; Liao, Albert Taiching</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-adfa27a0a35828b1289d6d9025e3b7445f5671bb0f0d143095987b7375765a5c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Canine</topic><topic>Chemotherapy</topic><topic>Cyclophosphamide</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Dog Diseases - drug therapy</topic><topic>Dogs</topic><topic>Doxorubicin - therapeutic use</topic><topic>Female</topic><topic>Lymphoma</topic><topic>Lymphoma - drug therapy</topic><topic>Lymphoma - veterinary</topic><topic>Male</topic><topic>Prednisone - therapeutic use</topic><topic>Recurrence</topic><topic>Relapse</topic><topic>Vincristine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Shang-Lin</creatorcontrib><creatorcontrib>Lee, Jih-Jong</creatorcontrib><creatorcontrib>Liao, Albert Taiching</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The veterinary journal (1997)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Shang-Lin</au><au>Lee, Jih-Jong</au><au>Liao, Albert Taiching</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of temporal association of relapse of canine multicentric lymphoma with components of the CHOP protocol: Is cyclophosphamide the weakest link?</atitle><jtitle>The veterinary journal (1997)</jtitle><addtitle>Vet J</addtitle><date>2016-07</date><risdate>2016</risdate><volume>213</volume><spage>87</spage><epage>89</epage><pages>87-89</pages><issn>1090-0233</issn><eissn>1532-2971</eissn><abstract>•Dogs with lymphoma relapsed significantly more frequently when cyclophosphamide was used as an induction agent.•New chemotherapy protocols which replace cyclophosphamide with other agent/s might improve outcomes.•The cumulative or synergistic effects of previously used drugs did not affect treatment.•Relatively higher dose rates in small dogs may produce better responses and longer remission times.
Combination chemotherapy, using cyclophosphamide, hydroxydaunorubicin, vincristine and prednisolone (CHOP), is the most commonly used treatment for canine lymphoma. Most affected dogs respond during the initial stages of chemotherapy, but many relapse. The aim of this study was to evaluate the relationship between the use of specific chemotherapy drugs and clinical relapse, using the modified Madison-Wisconsin, 25 week chemotherapy protocol. Forty-one of 68 dogs affected with multicentric lymphoma relapsed during the treatment period. Relapse occurred more frequently after the administration of cyclophosphamide (n = 24; P < 0.01), compared with vincristine (n = 9) or doxorubicin (n = 5). Therefore, the therapeutic outcome of traditional CHOP-based chemotherapy might be improved by replacing cyclophosphamide with other cytotoxic drugs.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>27240922</pmid><doi>10.1016/j.tvjl.2016.04.013</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1090-0233 |
| ispartof | The veterinary journal (1997), 2016-07, Vol.213, p.87-89 |
| issn | 1090-0233 1532-2971 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1793216165 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Antineoplastic Combined Chemotherapy Protocols - therapeutic use Canine Chemotherapy Cyclophosphamide Cyclophosphamide - therapeutic use Dog Diseases - drug therapy Dogs Doxorubicin - therapeutic use Female Lymphoma Lymphoma - drug therapy Lymphoma - veterinary Male Prednisone - therapeutic use Recurrence Relapse Vincristine - therapeutic use |
| title | Assessment of temporal association of relapse of canine multicentric lymphoma with components of the CHOP protocol: Is cyclophosphamide the weakest link? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T04%3A58%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20temporal%20association%20of%20relapse%20of%20canine%20multicentric%20lymphoma%20with%20components%20of%20the%20CHOP%20protocol:%20Is%20cyclophosphamide%20the%20weakest%20link?&rft.jtitle=The%20veterinary%20journal%20(1997)&rft.au=Wang,%20Shang-Lin&rft.date=2016-07&rft.volume=213&rft.spage=87&rft.epage=89&rft.pages=87-89&rft.issn=1090-0233&rft.eissn=1532-2971&rft_id=info:doi/10.1016/j.tvjl.2016.04.013&rft_dat=%3Cproquest_cross%3E1793216165%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1793216165&rft_id=info:pmid/27240922&rft_els_id=S1090023316300351&rfr_iscdi=true |